A brief history of antidepressant drug development: From tricyclics to beyond ketamine

Acta Neuropsychiatrica

Volumn 30, Issue 6, 2018, Pages 307-322

  Pereira, Vitor Silva ^a   Hiroaki Sato, Vinícius Antonio ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

AMPA receptors; antidepressant drugs; brain derived neurotrophic factor; ketamine; N methyl D aspartate receptors

Indexed keywords

BIOLOGICAL MARKER; FLUOXETINE; KETAMINE; MIRTAZAPINE; NEFAZODONE; REBOXETINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; BIOGENIC AMINE;

CLINICAL EFFECTIVENESS; DEPRESSION; DRUG MECHANISM; DRUG RESEARCH; GLUTAMATERGIC SYNAPSE; HUMAN; MONOAMINERGIC SYSTEM; NEUROBIOLOGY; NONHUMAN; PSYCHOPHARMACOLOGY; REVIEW; ANIMAL; BRAIN; DRUG DEVELOPMENT; DRUG EFFECT; HISTORY; MAJOR DEPRESSION; NERVE CELL;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIOGENIC MONOAMINES; BRAIN; DEPRESSIVE DISORDER, MAJOR; DRUG DEVELOPMENT; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; KETAMINE; NEURONS;

EID: 85058605868     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1017/neu.2017.39     Document Type: Review

References (154)

1. ORGANIZATION WH. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization, 2017; License: CC BY-NC-SA 3.0 IGO.
2. MILLAN MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370.
3. HINDMARCH I. Beyond the monoamine hypothesis: mechanisms, molecules and methods. Eur Psychiatry 2002;17(Suppl. 3): 294-299.
4. BERMAN RM, CAPPIELLO A, ANAND A et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-354.
5. ABDALLAH CG, ADAMS TG, KELMENDI B, ESTERLIS I, SANACORA G, KRYSTAL JH. Ketamine's mechanism of action: a path to rapid-acting antidepressants. Depress Anxiety 2016;33:689-697.
6. ZARATE CA JR., MACHADO-VIEIRA R. Ketamine: translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders. Mol Psychiatry 2017; 22:324-327.
7. BROWNE CA, LUCKI I. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol 2013;4:161.
8. BAN TA. Pharmacotherapy of mental illness - a historical analysis. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:709-727.
9. LEHMANN HE. Historical evolution of antidepressant drugs. International Network for the History of Neuropsychopharmacology. 1986, 18.
10. LEHMANN HE, BAN TA. The history of the psychopharmacology of schizophrenia. Can J Psychiatry 1997;42: 152-162.
11. COZANITIS DA. Daniel Bovet, Nobelist: muscle relaxants in anaesthesia: the role played by two neglected protagonists. Wien Med Wochenschr 2016;166:487-499.
12. DOMINO EF. History of modern psychopharmacology: a personal view with an emphasis on antidepressants. Psychosom Med 1999;61:591-598.
13. KUHN R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry 1958;115: 459-464.
14. AYD FJ, BLACKWELL B. Taylor Manor Hospital. Discoveries in biological psychiatry. Philadelphia: Lippincott, 1970; 254 pp.
15. BAN TA. In memory of three pioneers. Int J Neuropsychopharmacol 2006;9:475-477.
16. ZELLER EA, BARSKY J, FOUTS JR, KIRCHHEIMER WF, VANORDEN LS. Influence of isonicotinic acid hydrazide (Inh) and 1-isonicotinyl-2-isopropyl hydrazide (Iih) on bacterial and mammalian enzymes. Experientia 1952;8:349-350.
17. LOPEZ-MUNOZ F, ALAMO C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 2009;15:1563-1586.
18. SALZER HM, LURIE ML. Anxiety and depressive states treated with isonicotinyl hydrazide (isoniazid). AMA Arch Neurol Psychiatry 1953;70:317-324.
19. LEWIS JG. Drug discovery; the evolution of modern medicines. Postgraduate Med J 1986;62:704.
20. LOPEZ-MUNOZ F, ALAMO C, JUCKEL G, ASSION HJ. Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors. J Clin Psychopharmacol 2007;27:555-559.
21. SIGG EB. Pharmacological studies with Tofranil. Can Psychiatr Assoc J 1959;4(Suppl.):75-85.
22. HERTING G, AXELROD J, WHITBY LG. Effect of drugs on the uptake and metabolism of H3-norepinephrine. J Pharmacol Exp Ther 1961;134:146-153.
23. SCHILDKRAUT JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509-522.
24. SCHILDKRAUT JJ, GORDON EK, DURELL J. Catecholamine metabolism in affective disorders. I. Normetanephrine and VMA excretion in depressed patients treated with imipramine. J Psychiatr Res 1965;3:213-228.
25. COPPEN A. The biochemistry of affective disorders. Br J Psychiatry 1967;113:1237-1264.
26. BRODIE BB, COMER MS, COSTA E, DLABAC A. The role of brain serotonin in the mechanism of the central action of reserpine. J Pharmacol Exp Ther 1966;152:340-349.
27. SHOPSIN B, FRIEDMAN E, GERSHON S. Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch Gen Psychiatry 1976;33:811-819.
28. SHOPSIN B, GERSHON S, GOLDSTEIN M, FRIEDMAN E, WILK S. Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacol Commun 1975;1:239-249.
29. COPPEN A, SHAW DM, FARRELL JP. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet 1963;1:79-81.
30. LAPIN IP, OXENKRUG GF. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969;1:132-136.
31. BAN TA. Pharmacotherapy of depression: a historical analysis. J Neural Transm (Vienna) 2001;108:707-716.
32. KUHN R. The imipramine story. In: Ayd FJ editor Discoveries in biological psychiatry. Philadelphia: JB Lippincott, 1970; p. 205-217.
33. BRODIE BB, BICKEL MH, SULSER F. Desmethylimipramine, a new type of antidepressant drug. Med Exp Int J Exp Med 1961;5:454-458.
34. FANGMANN P, ASSION HJ, JUCKEL G, GONZALEZ CA, LOPEZMUNOZ F. Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: tricyclics and tetracyclics. J Clin Psychopharmacol 2008;28:1-4.
35. IMS Institute for Healthcare Informatics. The use of medicines in the United States: review of 2011. In: Kleinrock M, editor. Parsippany, NJ, USA: IMS Institute for Healthcare Informatics, 2011.
36. ABBING-KARAHAGOPIAN V, HUERTA C, SOUVEREIN PC et al. Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications. Eur J Clin Pharmacol. 2014;70:849-857.
37. WONG DT, HORNG JS, BYMASTER FP, HAUSER KL, MOLLOY BB. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpro pylamine. Life Sci 1974;15:471-479.
38. LÓPEZ-MUÑOZ F, ÁLAMO C. Cuenca El triunfo de la política de diseño racional de psicofármacos: descubrimiento de la fluoxetina. In: Historia De La Psicofarmacologia, Vol 2, 2.1 edn. Madrid: Panamericana, 2007. p. 1195.
39. SAM. The efficacy of fluoxetine as an antidepressant in the short and long term. Int Clin Psychopharmacol 1989; 4(Suppl. 1):113-119.
40. FAGIUS J, OSTERMAN PO, SIDEN A, WIHOLM BE. Guillain-Barre syndrome following zimeldine treatment. J Neurol Neurosurg Psychiatry 1985;48:65-69.
41. PINCUS HA, TANIELIAN TL, MARCUS SC et al. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA 1998;279:526-531.
42. SZEGEDY-MASZAK M. The career of a celebrity pill. As Prozac's long reign comes to an end, experts are questioning its legacy. US News World Rep 2001;131:38-39.
43. SLINGSBY BT. The Prozac boom and its placebogenic counterpart - a culturally fashioned phenomenon. Med Sci Monit 2002;8:CR389-CR393.
44. NESTLER EJ. Antidepressant treatments in the 21st century. Biol Psychiatry 1998;44:526-533.
45. BOOIJ L, VAN DER DOES AJ, RIEDEL WJ. Monoamine depletion in psychiatric and healthy populations: review. Mol Psychiatry 2003;8:951-973.
46. DELGADO PL. Monoamine depletion studies: implications for antidepressant discontinuation syndrome. J Clin Psychiatry 2006;67(Suppl. 4):22-26.
47. MORENO FA, PARKINSON D, PALMER C et al. CSF neurochemicals during tryptophan depletion in individuals with remitted depression and healthy controls. Eur Neuropsychopharmacol 2010;20:18-24.
48. HOHMAN LB. A review of one hundred and forty-four cases of affective disorders - after seven years. Am J Psychiatry 1937;94:303-308.
49. AL-HARBI KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence 2012;6:369-388.
50. KEKS NA, BURROWS GD, COPOLOV DL et al. Beyond the evidence: is there a place for antidepressant combinations in the pharmacotherapy of depression? Med J Aust 2007;186:142-144.
51. World Health Organization CGF. Improving access and appropriate use of medicines for mental disorders. Geneva: World Health Organization, 2017; Available at http:// apps.who.int/iris/bitstream/10665/254794/1/9789241511421-eng.pdf. Accessed April 10, 2017.
52. MADDOX VH, GODEFROI EF, PARCELL RF. The synthesis of phencyclidine and other 1-arylcyclohexylamines. J Med Chem 1965;8:230-235.
53. DOMINO EF. Taming the ketamine tiger. 1965. Anesthesiology 2010;113:678-684.
54. ANILINE O, PITTS FN JR. Phencyclidine (PCP): a review and perspectives. Crit Rev Toxicol 1982;10:145-177.
55. DOMINO EF, CHODOFF P, CORSSEN G. Pharmacologic effects of Ci-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther 1965;6:279-291.
56. GJESSING J. Ketamine (Cl-581) in clinical anaesthesia. Acta Anaesthesiol Scand 1968;12:15-21.
57. CORSSEN G, DOMINO EF, BREE RL. Electroencephalographic effects of ketamine anesthesia in children. Anesth Analg 1969;48:141-147.
58. DUNDEE JW, BOVILL JG, CLARKE RS, PANDIT SK. Problems with ketamine in adults. Anaesthesia 1971;26:86.
59. PAGE P, MORGAN M, LOH L. Ketamine anaesthesia in paediatric procedures. Acta Anaesthesiol Scand 1972;16:155-160.
60. SUSSMAN DR. A comparative evaluation of ketamine anesthesia in children and adults. Anesthesiology 1974;40:459-464.
61. CORAZZA O, ASSI S, SCHIFANO F. From "Special K" to "Special M": the evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci Ther 2013; 19:454-460.
62. SANACORA G, SCHATZBERG AF. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology 2015;40:259-267.
63. COLLINGRIDGE GL, WATKINS JC. The NMDA receptor, 2nd edn. New York, NY: Oxford University Press Inc., 1994; 503 pp.
64. ANIS NA, BERRY SC, BURTON NR, LODGE D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methylaspartate. Br J Pharmacol 1983;79:565-575.
65. HARRISON NL, SIMMONDS MA. Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol 1985;84:381-391.
66. PERSSON J. Ketamine in pain management. CNS Neurosci Ther 2013;19:396-402.
67. JOHNSON JW, GLASGOW NG, POVYSHEVA NV. Recent insights into the mode of action of memantine and ketamine. Curr Opin Pharmacol 2015;20:54-63.
68. DU JARDIN KG, MULLER HK, ELFVING B, DALE E, WEGENER G, SANCHEZ C. Potential involvement of serotonergic signaling in ketamine's antidepressant actions: a critical review. Prog Neuropsychopharmacol Biol Psychiatry 2016;71: 27-38.
69. TRULLAS R, SKOLNICK P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990;185:1-10.
70. MOGHADDAM B. Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. J Neurochem 1993;60:1650-1657.
71. MOGHADDAM B, ADAMS B, VERMA A, DALY D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997;17:2921-2927.
72. MOGHADDAM B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psychiatry 2002;51:775-787.
73. NOWAK G, TRULLAS R, LAYER RT, SKOLNICK P, PAUL IA. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 1993;265:1380-1386.
74. SKOLNICK P, LAYER RT, POPIK P, NOWAK G, PAUL IA, TRULLAS R. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 1996;29:23-26.
75. KRYSTAL JH, SANACORA G, DUMAN RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 2013;73:1133-1141.
76. ABDALLAH CG, SANACORA G, DUMAN RS, KRYSTAL JH. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med 2015;66:509-523.
77. ZARATE CA JR., SINGH JB, CARLSON PJ et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatmentresistant major depression. Arch Gen Psychiatry 2006; 63:856-864.
78. ZARATE CA JR., BRUTSCHE N, LAJE G et al. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 2012; 72:331-338.
79. ZARATE CA JR., BRUTSCHE NE, IBRAHIM L et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012; 71:939-946.
80. LI N, LEE B, LIU RJ et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329:959-964.
81. AUTRY AE, ADACHI M, NOSYREVA E et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011;475:91-95.
82. LI N, LIU RJ, DWYER JM et al. Glutamate N-methyl-Daspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011;69:754-761.
83. PEREIRA VS, ROMANO A, WEGENER G, JOCA SR. Antidepressant-like effects induced by NMDA receptor blockade and NO synthesis inhibition in the ventral medial prefrontal cortex of rats exposed to the forced swim test. Psychopharmacology (Berl) 2015;232:2263-2273.
84. FELDER CC. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J 1995; 9:619-625.
85. ALDERTON WK, COOPER CE, KNOWLES RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001;357:593-615.
86. RAHIMIAN R, FAKHFOURI G, EJTEMAEI MEHR S et al. Tropisetron attenuates amyloid-beta-induced inflammatory and apoptotic responses in rats. Eur J Clin Invest 2013;43:1039-1051.
87. FLORENZANO F, VISCOMI MT, AMADIO S, D'AMBROSI N, VOLONTE C, MOLINARI M. Do ATP and NO interact in the CNS? Prog Neurobiol 2008;84:40-56.
88. PEREIRA VS, CASAROTTO PC, HIROAKI-SATO VA, SARTIM AG, GUIMARAES FS, JOCA SR. Antidepressant-and anticompulsivelike effects of purinergic receptor blockade: involvement of nitric oxide. Eur Neuropsychopharmacol 2013;23:1769-1778.
89. GARTHWAITE J, GARTHWAITE G, PALMER RM, MONCADA S. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol 1989; 172:413-416.
90. GUIX FX, URIBESALGO I, COMA M, MUNOZ FJ. The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol 2005;76:126-152.
91. JOCA SR, MOREIRA FA, WEGENER G. Atypical neurotransmitters and the neurobiology of depression. CNS Neurol Disord Drug Targets 2015;14:1001-1011.
92. CALABRESE V, MANCUSO C, CALVANI M, RIZZARELLI E, BUTTERFIELD DA, STELLA AM. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci 2007;8:766-775.
93. JEFFERYS D, FUNDER J. Nitric oxide modulates retention of immobility in the forced swimming test in rats. Eur J Pharmacol 1996;295:131-135.
94. YILDIZ F, ERDEN BF, ULAK G, UTKAN T, GACAR N. Antidepressant-like effect of 7-nitroindazole in the forced swimming test in rats. Psychopharmacology (Berl) 2000; 149:41-44.
95. JOCA SR, GUIMARAES FS. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology (Berl) 2006;185:298-305.
96. ZHOU QG, HU Y, HUA Y et al. Neuronal nitric oxide synthase contributes to chronic stress-induced depression by suppressing hippocampal neurogenesis. J Neurochem 2007;103:1843-1854.
97. MUTLU O, ULAK G, LAUGERAY A, BELZUNG C. Effects of neuronal and inducible NOS inhibitor 1-[2- (trifluoromethyl) phenyl] imidazole (TRIM) in unpredictable chronic mild stress procedure in mice. Pharmacol Biochem Behav 2009;92:82-87.
98. ZHANG GF, WANG N, SHI JY et al. Inhibition of the L-arginine-nitric oxide pathway mediates the antidepressant effects of ketamine in rats in the forced swimming test. Pharmacol Biochem Behav 2013;110:8-12.
99. LIEBENBERG N, JOCA S, WEGENER G. Nitric oxide involvement in the antidepressant-like effect of ketamine in the Flinders sensitive line rat model of depression. Acta Neuropsychiatr 2015;27:90-96.
100. LIU J, MOGHADDAM B. Regulation of glutamate efflux by excitatory amino acid receptors: evidence for tonic inhibitory and phasic excitatory regulation. J Pharmacol Exp Ther 1995;274:1209-1215.
101. KOIKE H, IIJIMA M, CHAKI S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 2011;224:107-111.
102. MAENG S, ZARATE CA JR., DU J et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008;63:349-352.
103. LI X, TIZZANO JP, GRIFFEY K, CLAY M, LINDSTROM T, SKOLNICK P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 2001;40:1028-1033.
104. LINDHOLM JS, AUTIO H, VESA L et al. The antidepressantlike effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf (+)/(-) heterozygous null mice. Neuropharmacology 2012;62:391-397.
105. BARBON A, CARACCIOLO L, ORLANDI C et al. Chronic antidepressant treatments induce a time-dependent upregulation of AMPA receptor subunit protein levels. Neurochem Int 2011;59:896-905.
106. SANACORA G, TRECCANI G, POPOLI M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012;62:63-77.
107. JOURDI H, HSU YT, ZHOU M, QIN Q, BI X, BAUDRY M. Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation. J Neurosci 2009;29:8688-8697.
108. LEPACK AE, FUCHIKAMI M, DWYER JM, BANASR M, DUMAN RS. BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol 2014;18. pii: pyu033.
109. LIU RJ, LEE FS, LI XY, BAMBICO F, DUMAN RS, AGHAJANIAN GK. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry 2012; 71:996-1005.
110. RICCI V, MARTINOTTI G, GELFO F et al. Chronic ketamine use increases serum levels of brain-derived neurotrophic factor. Psychopharmacology (Berl) 2011;215:143-148.
111. COSTA-MATTIOLI M, MONTEGGIA LM. mTOR complexes in neurodevelopmental and neuropsychiatric disorders. Nat Neurosci 2013;16:1537-1543.
112. YOON SC, SEO MS, KIM SH et al. The effect of MK-801 on mTOR/p70S6K and translation-related proteins in rat frontal cortex. Neurosci Lett 2008;434:23-28.
113. MAO L, TANG Q, SAMDANI S, LIU Z, WANG JQ. Regulation of MAPK/ERK phosphorylation via ionotropic glutamate receptors in cultured rat striatal neurons. Eur J Neurosci 2004;19:1207-1216.
114. WANG JQ, TANG Q, PARELKAR NK et al. Glutamate signaling to Ras-MAPK in striatal neurons: mechanisms for inducible gene expression and plasticity. Mol Neurobiol 2004; 29:1-14.
115. NAGAHARA AH, TUSZYNSKI MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 2011;10:209-219.
116. GRIMES CA, JOPE RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001;65:391-426.
117. ZONCU R, EFEYAN A, SABATINI DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35.
118. BEUREL E, SONG L, JOPE RS. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry 2011;16:1068-1070.
119. LIU RJ, FUCHIKAMI M, DWYER JM, LEPACK AE, DUMAN RS, AGHAJANIAN GK. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 2013;38: 2268-2277.
120. CHIU CT, SCHEUING L, LIU G et al. The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress. Int J Neuropsychopharmacol 2015;18: pii: pyu102.
121. BEUREL E, GRIECO SF, JOPE RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther 2015;148:114-131.
122. MA XC, DANG YH, JIA M et al. Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One 2013;8:e56053.
123. CADDY C, GIAROLI G, WHITE TP, SHERGILL SS, TRACY DK. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol 2014;4:75-99.
124. SANACORA G, FRYE MA, MCDONALD W et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 2017;74:399-405.
125. SANACORA G, HEIMER H, HARTMAN D et al. Balancing the promise and risks of ketamine treatment for mood disorders. Neuropsychopharmacology 2017;42:1179-1181.
126. WILKINSON ST, SANACORA G. Considerations on the off-label use of ketamine as a treatment for mood disorders. JAMA 2017;318:793-794.
127. KISELYCZNYK C, JURY NJ, HALLADAY LR et al. NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDAGluN2B antagonism. Behav Brain Res 2015;287:89-95.
128. LIMA-OJEDA JM, VOGT MA, PFEIFFER N et al. Pharmacological blockade of GluN2B-containing NMDA receptors induces antidepressant-like effects lacking psychotomimetic action and neurotoxicity in the perinatal and adult rodent brain. Prog Neuropsychopharmacol Biol Psychiatry 2013;45:28-33.
129. PRESKORN SH, BAKER B, KOLLURI S, MENNITI FS, KRAMS M, LANDEN JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008;28: 631-637.
130. POLESZAK E, STASIUK W, SZOPA A et al. Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice. Metab Brain Dis 2016;31:803-814.
131. LENER MS, KADRIU B, ZARATE CA JR. Ketamine and beyond: investigations into the potential of glutamatergic agents to treat depression. Drugs 2017;77:381-401.
132. IBRAHIM L, DIAZ GRANADOS N, JOLKOVSKY L et al. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol 2012;32:551-557.
133. WEED MR, BOOKBINDER M, POLINO J et al. Negative allosteric modulators selective for the NR2B subtype of the NMDA receptor impair cognition in multiple domains. Neuropsychopharmacology 2016;41:568-577.
134. SKOLNICK P, POPIK P, TRULLAS R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009; 30:563-569.
135. PAOLETTI P, BELLONE C, ZHOU Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 2013;14:383-400.
136. RAJAGOPAL L, BURGDORF JS, MOSKAL JR, MELTZER HY. GLYX-13 (rapastinel) ameliorates subchronic phencyclidine-and ketamine-induced declarative memory deficits in mice. Behav Brain Res 2016;299:105-110.
137. BURGDORF J, ZHANG XL, WEISS C et al. The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. Neurobiol Aging 2011;32:698-706.
138. BURGDORF J, ZHANG XL, NICHOLSON KL et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 2013;38:729-742.
139. BURCH RM, AMIN KHAN M, HOUCK D et al. NMDA receptor glycine site modulators as therapeutics for depression: rapastinel has antidepressant activity without causing psychotomimetic side effects. Curr Neuropharmacol 2016, doi: 10.2174/1570159X14666160202121319.
140. BURGDORF J, ZHANG XL, WEISS C et al. The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus. Neuroscience 2015; 308:202-211.
141. LU Y, WANG C, XUE Z et al. PI3K/AKT/mTOR signalingmediated neuropeptide VGF in the hippocampus of mice is involved in the rapid onset antidepressant-like effects of GLYX-13. Int J Neuropsychopharmacol 2015;18: pii: pyu110.
142. MOSKAL JR, BURGDORF JS, STANTON PK et al. The development of rapastinel (formerly GLYX-13); a rapid acting and long lasting antidepressant. Curr Neuropharmacol 2017;15:47-56.
143. ZARATE C, DUMAN RS, LIU G, SARTORI S, QUIROZ J, MURCK H. New paradigms for treatment-resistant depression. Ann N Y Acad Sci 2013;1292:21-31.
144. PRESKORN S, MACALUSO M, MEHRA DO et al. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract 2015;21:140-149.
145. MACHADO-VIEIRA R, HENTER ID, ZARATE CA JR. New targets for rapid antidepressant action. Prog Neurobiol 2017;152:21-37.
146. LEUNG LY, BAILLIE TA. Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. J Med Chem 1986;29:2396-2399.
147. SALAT K, SIWEK A, STAROWICZ G et al. Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: role of activity at NMDA receptor. Neuropharmacology 2015;99:301-307.
148. ZHAO X, VENKATA SL, MOADDEL R et al. Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Br J Clin Pharmacol 2012;74:304-314.
149. ZANOS P, MOADDEL R, MORRIS PJ et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 2016;533:481-486.
150. FARLEY S, APAZOGLOU K, WITKIN JM, GIROS B, TZAVARA ET. Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. Int J Neuropsychopharmacol 2010;13:1207-1218.
151. NATIONS KR, BURSI R, DOGTEROM P et al. Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection. Drugs R D 2012;12:127-139.
152. NATIONS KR, DOGTEROM P, BURSI R et al. Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial. J Psychopharmacol 2012;26: 1525-1539.
153. DUTTA A, MCKIE S, DEAKIN JF. Ketamine and other potential glutamate antidepressants. Psychiatry Res 2015;225:1-13.
154. RANTAMAKI T, YALCIN I. Antidepressant drug action - from rapid changes on network function to network rewiring. Prog Neuropsychopharmacol Biol Psychiatry 2016;64:285-292.